A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Massachusetts General Hospital
Ono Pharmaceutical Co. Ltd
Ohio State University Comprehensive Cancer Center
Ono Pharmaceutical Co. Ltd
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
University of Nebraska
University of Chicago
Barbara Ann Karmanos Cancer Institute
Benaroya Research Institute
Gilead Sciences
University of Chicago
TG Therapeutics, Inc.
University of California, San Francisco
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
St. Luke's-Roosevelt Hospital Center